ADVENTRX Pharmaceuticals submits a NDA for its vinorelbine injectable emulsion ADVENTRX Pharmaceuticals, Inc. announced today that it has submitted a fresh Drug Program to the U.S. Food and Drug Administration for its product applicant ANX-530 . I congratulate our development team for achieving this essential milestone on routine in December, as planned. ANX-530 gets the potential to offer important benefits to cancer individuals, and we anticipate working with FDA towards its authorization, stated Brian M. Culley, Principal Executive Officer of ADVENTRX. The ANX-530 NDA submission is a key step in our technique to create valuable products that improve the performance of presently approved medicines.Blakely, M.D., Ashfaq Shuaib, M.D., Vladimir Hachinski, M.D., D.Sc., Shelagh B. Coutts, M.B., Ch.B., M.D., Demetrios J. Sahlas, M.D., Phil Teal, M.D., Samuel Yip, M.D., J. David Spence, M.D., Brian Buck, M.D., Steve Verreault, M.D., Leanne K. Casaubon, M.D., Andrew Penn, M.D., Daniel Selchen, M.D., Albert Jin, M.D., David Howse, M.D., Manu Mehdiratta, M.D., Karl Boyle, M.B., B.Ch., Richard Aviv, M.B., Ch.B., Moira K. Kapral, M.D., and Muhammad Mamdani, Pharm.D., M.P.H. For the EMBRACE Investigators and Coordinators: Atrial Fibrillation in Individuals with Cryptogenic Stroke The prevention of stroke related to atrial fibrillation is a global public health priority.